NCT00644709 - A Study Of Atorvastatin For The Treatment Of High Cholesterol In Patients At High Risk Of Coronary Heart Disease (CHD) | Biotech Hunter

Enrollment

196

Participants

Timeline

Start Date

September 30, 2003

Study Completion Date

March 31, 2005

Conditions

Dyslipidemias

Interventions

DRUG

Atorvastatin

Atorvastatin tablets at starting doses of 10, 20, 40, or 80 mg once daily. Three dose adjustments were allowed at baseline, Week 17, and Week 34. Patients who did not meet the LDL-C target at any of these time points had their doses doubled except for those who were on the 80 mg dose. Treatment was given for 52 weeks.

Trial Locations (15)

1180

Pfizer Investigational Site, Brussels

2018

Pfizer Investigational Site, Antwerp

2170

Pfizer Investigational Site, Merksem

2610

Pfizer Investigational Site, Wilrijk

2640

Pfizer Investigational Site, Mortsel

2800

Pfizer Investigational Site, Mechelen

2930

Pfizer Investigational Site, Brasschaat

4100

Pfizer Investigational Site, Seraing

6060

Pfizer Investigational Site, Gilly (charleroi)

7100

Pfizer Investigational Site, La Louvière

8750

Pfizer Investigational Site, Wingene

8800

Pfizer Investigational Site, Roeselare

8930

Pfizer Investigational Site, Menen

9000

Pfizer Investigational Site, Ghent

B-3600

Pfizer Investigational Site, Genk

All Listed Sponsors

lead

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

INDUSTRY